文献速递冠心病

急性冠脉综合征PCI术后普拉格雷或替格瑞洛单药治疗对比双联抗血小板治疗的landmark分析:NEOMINDSET试验

Prasugrel or ticagrelor monotherapy vs dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndromes: a landmark analysis from the NEOMINDSET trial.
PubMed 文献 · Eur Heart J · 2025-12-19

NEOMINDSET试验随机分配3410例成功行PCI的ACS患者,比较强效P2Y12抑制剂单药与标准DAPT 12个月。预设30天landmark分析显示,单药组0-30天缺血复合终点高于DAPT组(3.3% vs 1.8%),但31-365天两组缺血发生率相似(各3.8%);单药组出血事件在30天内及之后均持续更低。

要点

  • ACS患者PCI术后早期(0-30天)停用阿司匹林采用P2Y12抑制剂单药,缺血风险高于DAPT。
  • 30天后单药治疗缺血风险与DAPT相当,出血风险持续更低。
  • 临床决策需权衡早期缺血与全程出血风险,个体化选择抗血小板策略。

核心结论

  • 预设30天landmark分析提示,与DAPT相比,单药治疗在最初30天缺血风险增加,但此后不再增加;无阿司匹林策略在30天内及之后均与更少出血事件相关。

研究设计与样本

  • NEOMINDSET随机对照试验的预设landmark分析,纳入3410例因急性冠脉综合征入院4天内成功行药物洗脱支架PCI的患者,随机接受强效P2Y12抑制剂单药(普拉格雷或替格瑞洛)或标准DAPT(阿司匹林加强效P2Y12抑制剂)治疗12个月,分析早期(0-30天)和晚期(31-365天)随访事件。

关键数值与推荐

  • 缺血复合终点定义为全因死亡、心肌梗死、卒中或紧急靶血管血运重建的复合终点。
  • 出血终点定义为BARC 2、3或5型出血。

临床怎么用

  • ACS患者PCI术后早期(30天内)停用阿司匹林采用P2Y12抑制剂单药需警惕缺血风险增加。
  • 30天后转换为P2Y12抑制剂单药可减少出血且不增加缺血事件,可考虑用于高出血风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention in patients with acute coronary syndrome remains uncertain. This analysis examined the temporal patterns of ischaemic and bleeding risks of early aspirin withdrawal compared with DAPT. METHODS: NEO-MINDSET randomized 3410 acute coronary syndrome patients undergoing successful percutaneous coronary intervention with drug-eluting stents within 4 days of hospital admission to either potent P2Y12 inhibitor monotherapy (prasugrel or ticagrelor) or standard DAPT (aspirin plus a potent P2Y12 inhibitor) for 12 months. This prespecified landmark analysis examined early (0-30 days) and late (31-365 days) follow-up events. Co-primary outcomes were (i) the composite of all cause death, myocardial infarction, stroke, or urgent target-vessel revascularization (ischaemic outcome) and (ii) Bleeding Academic Research Consortium type 2, 3, or 5 bleeding. RESULTS: At 30 days, the composite ischaemic outcome occurred in 3.3% of patients receiving monotherapy vs 1.8% with DAPT (risk difference 1.5%, 95% confidence interval .4%-2.6%; P = .006). Bleeding occurred in .6% vs 1.5% (risk difference -.8%, 95% confidence interval -1.5%-.1%; P = .018). In the landmark analysis between Days 31 and 365, ischaemic outcome rates were similar between study groups (3.8% each; P = .977), while bleeding remained less frequent with monotherapy (1.3% vs 3.5%; risk difference -2.2%, 95% confidence interval -3.2%-1.1%; P > .001). CONCLUSIONS: This prespecified 30-day landmark analysis suggests an excess of ischaemic risk with monotherapy vs DAPT in the first 30 days but not thereafter, whereas an aspirin-free strategy was consistently associated with fewer bleeding events within and after 30 days.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Tavares, Guimarães, Franken, et al. Prasugrel or ticagrelor monotherapy vs dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndromes: a landmark analysis from the NEOMINDSET trial. Eur Heart J. 2025. PMID: 41412791. doi:10.1093/eurheartj/ehaf1050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。